VPTDF - Kings College London Receives VMS+3.0 Ventripoint Whole Heart Analysis System
(TheNewswire)
First VMS+3.0 in UK and SeventhHospital to Adopt the Latest VMS Technology
Toronto, Ontario – TheNewswire –January 4, 2021 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to announce that the Company’sproprietary VMS+3.0 whole-heart analysis system has been installed atKings College Hospital (KCH) in London. KCH is a major research andclinical centre in the UK.
“This will help us evaluate patients with COVID-19,who are known to have acute right-heart dilation and systolicdysfunction, and many develop chronic symptoms,” stated Dr. MarkMonaghan, Director of Non-Invasive Cardiology at KCH. “It isimportant to compare the response of the heart to COVID-19 with otherknown heart conditions, which can also be assessed with theVMS+3.0.”
The NHS in the UK has announced an initiative to open40 new specialist clinics for COVID-19 patients with continuingsymptoms, “long COVID”, to build an expertise in assessing andtreating long-COVID patients(https://www.england.nhs.uk/2020/11/nhs-launches-40-long-covid-clinics-to-tackle-persistent-symptoms/). A study from King’s College London foundthat older people, women and those with a greater number of differentsymptoms in the first week of their illness were more likely todevelop long COVID with one in 10 still unable to shake off the sideeffects eight weeks after infection.
The Company estimates that 40,000 VMS+3.0 units wouldbe required based on standard-of-care guidelines to effectivelydiagnose, monitor and manage the health of patients with congenitalheart disease, pulmonary hypertension, suffering cardiotoxicity due tochemotherapy and COVID-19 infected patients.
About Kings College Hospital London
King's College Hospital (KCH) isa major traumacentre in DenmarkHill , Camberwell inthe London Borough ofLambeth . It serves an inner city population of 700,000 in the Londonboroughs of Southwark and Lambeth , and also serves asa tertiary referral centre in certain specialties to millions ofpeople in southern England. It is a large teachinghospital and is, with Guy'sHospital and St. Thomas'Hospital , the location of King's College LondonSchool of Medicine and one of theinstitutions that comprise the King's HealthPartners , an academic health sciencecentre .
KCH is a centre of excellence for heart disease andprimary angioplasty. It recently became one of the first hospitals inLondon to use a biodegradable heart stent, which dissolves after thevessel has healed and no longer needs support. In tandem with ourcardiac colleagues at Guy's and St Thomas' NHS Foundation Trust,King's also runs the largest aortic valve replacement programme in theUK.
The Harris Birthright Unit at KCH is one of the largestfetal medicine units of its kind in the world, seeing 15,000 women andtheir unborn babies each year. The unit provides specialist testingand treatment for babies with abnormalities in the womb, includingheart defects.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Mr. Jonathan Robinson
Email :JRobinson@oakhillfinancial.ca
Phone: (416)669-1001?????? ????????????
Or
Mr. Clay Chase
Email: cc@sdthc.com
Phone: 858-456-7300
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differ materially from those currentlyanticipated due to a number of factors and risks. Factors which couldmaterially affect such forward-looking information are described inthe risk factors in the Company's most recent annual management'sdiscussion and analysis that is available on the Company's profile onSEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2021 TheNewswire - All rights reserved.